Sun Pharmaceutical Industries Sees Sharp Open Interest Surge Amid Bullish Market Signals

Open Interest and Volume Dynamics

On 20 Feb 2026, Sun Pharmaceutical Industries Ltd (NSE: SUNPHARMA) recorded an open interest of 1,44,069 contracts in its derivatives segment, marking an 11.93% increase from the previous day's 1,28,711 contracts. This rise of 15,358 contracts is significant, reflecting heightened trader interest and positioning ahead of potential market moves. The volume for the day stood at 83,218 contracts, indicating robust trading activity supporting the OI expansion.

The futures segment alone accounted for a value of approximately ₹1,60,746.91 lakhs, while the options segment's notional value was substantially higher at ₹34,117.96 crores. The combined derivatives turnover thus reached ₹1,62,034.19 lakhs, underscoring the stock's liquidity and attractiveness among derivatives traders.

Price Performance and Technical Indicators

Sun Pharma's underlying stock price closed at ₹1,724, registering a 0.79% gain on the day, outperforming the Pharmaceuticals & Biotechnology sector's 0.19% rise and the Sensex's 0.62% advance. The stock is trading above all key moving averages—5-day, 20-day, 50-day, 100-day, and 200-day—indicating a strong uptrend and positive technical momentum.

However, delivery volumes tell a slightly different story. On 19 Feb, the delivery volume was 7.69 lakh shares, which declined by 6.56% compared to the five-day average delivery volume. This suggests a marginal reduction in long-term investor participation, possibly offset by increased speculative activity in the derivatives market.

Market Positioning and Directional Bets

The surge in open interest, coupled with rising volumes and price appreciation, points to increased bullish positioning by market participants. Traders appear to be building long futures and call option positions, anticipating further upside in Sun Pharma's stock price. The elevated options notional value supports this view, as options are often used for leveraged directional bets or hedging strategies.

Given the stock's large-cap status with a market capitalisation of ₹4,14,077.23 crores and a Mojo Score of 62.0, the recent downgrade from a Buy to a Hold rating on 16 Feb 2026 by MarketsMOJO reflects a cautious stance amid evolving market conditions. The downgrade suggests that while the stock remains fundamentally sound, investors should monitor near-term volatility and sector dynamics closely.

Liquidity and Trading Implications

Sun Pharma's liquidity remains robust, with the stock capable of supporting trade sizes up to ₹4.11 crores based on 2% of the five-day average traded value. This liquidity is crucial for institutional investors and large traders looking to execute sizeable positions without significant market impact.

The combination of rising open interest and strong liquidity suggests that the derivatives market is actively absorbing new positions, which could translate into increased volatility and trading opportunities in the near term. Investors should watch for changes in put-call ratios and strike-wise open interest to better gauge market sentiment and potential price targets.

Sector and Market Context

The Pharmaceuticals & Biotechnology sector has shown moderate gains recently, with Sun Pharma outperforming its peers. The sector's performance is influenced by regulatory developments, patent expiries, and global demand for generic medicines. Sun Pharma's ability to maintain its technical strength amid these factors highlights its resilience and market leadership.

However, the downgrade to a Hold rating by MarketsMOJO signals that investors should remain vigilant. The Mojo Grade of Hold, down from Buy, reflects a tempered outlook based on valuation concerns and sector headwinds. The stock's Market Cap Grade of 1 indicates its large-cap stature but also suggests limited room for aggressive upside in the short term.

Investor Takeaway and Outlook

The recent surge in open interest and volume in Sun Pharma's derivatives market signals increased speculative interest and potential directional bets favouring an upward trajectory. The stock's technical positioning above all major moving averages supports this bullish outlook in the short to medium term.

Nonetheless, the slight decline in delivery volumes and the recent rating downgrade advise caution. Investors should consider the broader sector environment, valuation metrics, and upcoming corporate developments before committing fresh capital.

Monitoring derivatives data such as changes in open interest by strike price, put-call ratios, and futures premium will provide valuable insights into evolving market sentiment. Given Sun Pharma's large-cap status and liquidity, it remains a key stock to watch within the Pharmaceuticals & Biotechnology sector.

Summary

Sun Pharmaceutical Industries Ltd's derivatives market activity on 20 Feb 2026 reveals a strong increase in open interest by nearly 12%, supported by healthy volumes and a positive price trend. While the stock outperforms its sector and the Sensex, a cautious Hold rating from MarketsMOJO reflects tempered expectations amid sector challenges. Investors should balance the bullish technical signals with fundamental considerations and evolving market dynamics to make informed decisions.

Limited Period Only. Start at Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Get 71% Off →